Literature DB >> 8484770

Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3.

F Mollinedo1, R Martínez-Dalmau, M Modolell.   

Abstract

We have found that the alkyl-lysophospholipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) was able to induce apoptosis in human promyelocytic HL-60 leukemic cells, as evidenced by the internucleosomal degradation of the cellular DNA into the characteristic 180-200 bp DNA fragments. This effect was observed after short periods of cell incubation (6 h) with low doses of ET-18-OCH3 (3 micrograms/ml). Furthermore, we found that ET-18-OCH3 also induced rapidly apoptosis in human promonocytic U937 leukemic cells. In contrast, 3T3 fibroblasts were resistant to the alkyl-lysophospholipid. ET-18-OCH3 induced apoptotic cell death of tumor epithelial-like HELA cells, but this process required prolonged times of incubation. These data demonstrate that ET-18-OCH3 promotes a rapid and selective programmed cell death in human leukemic cells, providing an explanation to the previously described cytotoxic effects of this compound on leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484770     DOI: 10.1006/bbrc.1993.1458

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.

Authors:  Kerstin Danker; Werner Reutter; Geo Semini
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  The ether lipid ET-18-OCH3 increases cytosolic Ca2+ concentrations in Madin Darby canine kidney cells.

Authors:  C R Jan; S N Wu; C J Tseng
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.

Authors:  C Cabaner; C Gajate; A Macho; E Muñoz; M Modolell; F Mollinedo
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway.

Authors:  Sung-Chul Lim; Keshab Raj Parajuli; Song Iy Han
Journal:  Tumour Biol       Date:  2015-11-28

5.  The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells.

Authors:  F Mollinedo; C Gajate; M Modolell
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

6.  Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis.

Authors:  Vitaly A Selivanov; Pedro Vizán; Faustino Mollinedo; Teresa W M Fan; Paul W N Lee; Marta Cascante
Journal:  BMC Syst Biol       Date:  2010-10-06

7.  Exogenous ether lipids predominantly target mitochondria.

Authors:  Lars Kuerschner; Doris Richter; Hans Kristian Hannibal-Bach; Anne Gaebler; Andrej Shevchenko; Christer S Ejsing; Christoph Thiele
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

8.  In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.

Authors:  Rubén E Varela-M; Janny A Villa-Pulgarin; Edward Yepes; Ingrid Müller; Manuel Modolell; Diana L Muñoz; Sara M Robledo; Carlos E Muskus; Julio López-Abán; Antonio Muro; Iván D Vélez; Faustino Mollinedo
Journal:  PLoS Negl Trop Dis       Date:  2012-04-10

9.  Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine.

Authors:  Ximena Bonilla; El-Habib Dakir; Faustino Mollinedo; Consuelo Gajate
Journal:  Oncotarget       Date:  2015-06-10

Review 10.  Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.